GlassScriptPhysician profile
Ziad W Ghamra
NPI 1023058732
$3,798.42
in general payments reported to CMS, 2019-2025
26 companies · $1,108 in 2025
The $1,108 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $270 · 2020: $251 · 2021: $635 · 2022: $446 · 2023: $494 · 2024: $594 · 2025: $1,108.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,196.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $691.42 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Insmed, INC. | $506.91 | 2020-2025 | Arikayce, Brinsupri |
| Astrazeneca Pharmaceuticals LP | $490.27 | 2019-2025 | Fasenra, Tezspire, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $406.92 | 2019-2025 | Jascayd, Ofev |
| Actelion Pharmaceuticals US, INC. | $319.02 | 2020-2025 | Uptravi, Opsumit |
| United Therapeutics Corporation | $274.02 | 2019-2025 | Tyvaso, Orenitram, Remodulin |
| Abiomed | $136.36 | 2021 | |
| Intuitive Surgical, INC. | $134.61 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $129.03 | 2021-2025 | Glassia |
| Janssen Pharmaceuticals, INC | $105.29 | 2020-2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $101.89 | 2019-2022 | |
| Shionogi INC | $85.55 | 2022-2025 | Fetroja |
| Regeneron Healthcare Solutions, INC. | $67.38 | 2024-2025 | Dupixent |
| Baxter Healthcare | $49.29 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
| Tactile Systems Technology INC | $38.15 | 2024 | Entre Plus, Flexitouch Plus |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pulmonx Corporation | $35.27 | 2022 | |
| Electromed, INC. | $34.09 | 2022-2025 | Smartvest |
| Paratek Pharmaceuticals, INC. | $31.56 | 2021-2022 | |
| Nabriva Therapeutics, Plc | $24.51 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $22.09 | 2022 | |
| Vapotherm INC | $21.90 | 2022 | |
| Grifols USA, LLC | $21.29 | 2021 | |
| Mallinckrodt Hospital Products INC. | $20.65 | 2023 | Terlivaz |
| Philips North America LLC | $18.19 | 2020 | |
| Resmed Corp | $17.23 | 2023 | |
| Harmony Biosciences LLC | $15.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ziad Ghamra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.